Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
1.775
-0.075 (-4.05%)
Aug 28, 2026, 1:43 PM EDT - Market open

Gain Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
---0.060.130.13
Revenue Growth
----58.40%-0.96%-
Gross Profit
-9.99-10.07-10.65-11.32-8.11-7.03
Operating Income
-19.3-18.73-20.36-22.26-17.79-13.84
Net Income
-20.11-20.16-20.41-22.27-17.59-13.89
Earnings Per Share
-0.51-0.61-0.89-1.71-1.48-1.37
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
13.0820.8410.3916.7922.0836.88
Total Debt
0.610.730.651.031.271.61
Net Cash (Debt)
12.4720.119.7315.7720.8135.27
Net Cash Growth
107.44%106.57%-38.27%-24.22%-41.01%466.03%
Net Cash Per Share
0.320.610.431.211.753.47

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-18.95-18.47-18.87-18.87-14.69-12.37
Capital Expenditures
---0.02-0.02-0.12-0.09
Free Cash Flow
-18.95-18.47-18.9-18.88-14.81-12.46
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Margin
----40336.86%-13410.18%-10332.05%
Pretax Margin
----40210.67%-13191.92%-10368.70%
Profit Margin
----40354.33%-13262.02%-10371.70%
FCF Margin
----34217.53%-11166.38%-9303.42%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
---894.85280.42481.65